Top 5 News Stories 6/30-7/6
1. Bristol’s Amylin Deal Heralds Acquisition Hunger Bloomberg News – 7/03/12
Bristol-Myers Squibb Co.’s $5.3 billion deal to buy diabetes drugmaker Amylin Pharmaceuticals Inc. (AMLN) gives Bristol (BMY) immediate access to a market of growing medical need, while heralding a burgeoning hunger among pharmaceutical companies for acquisitions.
2. The time is now for health care change – Guest Opinion The Herald News – 07/04/2012
“In order for the Medicare program to be economically sustainable, the healthcare industry must shift its focus away from primarily treating illness to a more holistic approach aimed at keeping people healthy.”
3. Agios connects dots between enzyme and cancer Mass High Tech – 07/05/2012
Scientists at Cambridge-based biopharmaceutical company Agios Pharmaceuticals Inc. discovered new evidence that links metabolic enzyme and acute myeloid leukemia, a common form of adult cancer.
4. Biogen Idec tests hemophiliac protection for kids Mass High Tech – 07/05/2012
Children throughout the world suffering from hemophilia may be getting additional help from Weston-based Biogen Idec and Swedish Orphan Biovitrum (Sobi) of Stockholm, Sweden. The two companies are beginning clinical trials of hemophilia A and B product candidates that may last longer in the body to help clot blood for children at risk of uncontrolled bleeding.
5. FDA approves first rapid, take home HIV test USA Today – 7/04/12
The Food and Drug Administration has approved the first over-the-counter HIV test, allowing Americans to test themselves for the virus that causes AIDS in the privacy of their homes. The OraQuick test detects the presence of HIV in saliva collected using a mouth swab. The test is designed to return a result within 20 to 40 minutes.
Posted on July 6, 2012, in MassBio, News Roundup and tagged Agios, Amylin, Biogen Idec, Bristol-Myers Squibb Co., FDA, Hemophilia, HIV testing, Medicare, myeloid leukemia. Bookmark the permalink. Leave a Comment.